Back Policy/Litigation
Back Resolutions
Back Current Initiatives
Back Donate
Default image for pages

 <div class=”col-lg-9 content-page left-side”>
<section class=”section-a-single-resolutions resolutions-info top-content”>
<div class=”resolutions-contain”>
<div class=”top-content”>
<h4>Resolution Details</h4>
</div>
<div class=”bottom-content”>
<div class=”row-info”>
<strong>Company:</strong>
<p>Thermo Fisher Scientific Inc.</p>
</div>
<div class=”row-info”>
<strong>Year:</strong>
<p>2026 </p>
</div>
<div class=”row-info”>
<strong>Issue Area:</strong>
<p>Corporate Governance </p>
</div>

<div class=”row-info”>
<strong>Focus Area:</strong>
<p>Independent Board Chairs </p>
</div>
<div class=”row-info”>
<strong>Status:</strong>
<p>Filed</p>
</div>

<div class=”row-info”>

</a>
</div>
</div>
</div>
</section>

<section class=”section-b-single-resolutions content-blocks”>
<div class=”top-content editor-block”>
<div class=”content-block”>
<div class=”main-content”>
<h2>Resolution Text</h2>
<p><strong>RESOLVED</strong>: Shareholders request that the Board of Directors adopt an enduring policy, and amend the governing documents as necessary including the Corporate Governance Guidelines in order that 2 separate people hold the office of the Chairman and the office of the CEO as soon as possible.</p>
<p><strong>SUPPORTING STATEMENT</strong>:&nbsp;</p>
<p dir=”ltr”>The Chairman of the Board shall be an Independent Director. An independent Lead Director shall not be a substitute for an independent Board Chairman.<br>&nbsp;<br>The Board shall have the discretion to select an interim Chairman of the Board, who is not an Independent Director, to serve while the Board is required to seek an Independent Chairman of the Board on an accelerated basis. This policy could be phased in when there is a contract renewal for our current CEO or for the next CEO transition although it is better to adopt it now to obtain the maximum benefit.</p>
<p dir=”ltr”>An independent Board Chairman&nbsp;at all times improves corporate governance by bringing impartiality, objective oversight, and external expertise to board decisions, mitigating conflicts of interest, enhancing transparency, and boosting shareholder confidence.&nbsp;</p>
<p dir=”ltr”>This detached perspective allows the chairman to focus on&nbsp;shareholder interests,&nbsp;strengthen management accountability, and provide critical checks and balances, ultimately contributing to long-term sustainability and credibility.&nbsp;</p>
<p dir=”ltr”>An independent Board Chairman could also help Thermo Fisher Scientific (TMO) deal with headwinds like those that emerged in 2025:</p>
<p dir=”ltr”>TMO stock was at only $585 in late 2025 after trading at $672 in 2021 in spite of a robust stock market.</p>
<p dir=”ltr”>TMO faced a significant revenue headwind in China due to weak market conditions, a challenging pricing and reimbursement environment, and the impact of ongoing tariffs. The company estimated a $400 million hit to sales in China for the year.<br><br>The diagnostics and healthcare segments saw low single-digit declines in revenue growth, largely due to conditions in China. The analytical instruments segment also saw a decrease in adjusted operating income and operating margin.</p>
<p dir=”ltr”>Revenue from the academic and government sectors declined due to persistent funding constraints and grant cancellations by the National Institutes of Health (NIH).<br><br>TMO continued to reduce its headcount and consolidate facilities, incurring restructuring costs. These actions were primarily in the laboratory products and biopharma services segments.<br><br>Headwinds from tariffs and related foreign exchange impacts presented ongoing challenges to the company’s operations and profitability.&nbsp;<br><br>A Reuters exclusive reported in October 2024 (news widely discussed into 2025) that a Thermo Fisher plant making an infant RSV drug had breached FDA rules, including issues with procedures to prevent microbial contamination. While the FDA stated concerns were addressed, the news highlighted TMO manufacturing practice issues.<br><br>In January 2025, a journal retracted a Thermo Fisher study over ethical concerns that a tool used in the study violated standards of forensic genetics, as informed consent for DNA data collection in China could not be verified.&nbsp;</p>

</div>
</div>
</div>
<div class=”middle-content editor-block”>
<div class=”content-block”>
<div class=”main-content”>

</div>
</div>
</div>

</section>
</div>
<aside class=”col-xl-3 right-side”>
<div class=”column-contain”>

<div class=”position-groups”>
<div class=”row bs-1col node node–type-resolution node–view-mode-resolution-filers-only”>

<div class=”col-sm-12 col-md-8 bs-region bs-region–main”>
<div class=”views-element-container form-group”>
<div class=”view view-eva view-filers view-id-filers view-display-id-entity_view_3 js-view-dom-id-96619beb547210e21ae30c7c5355b846b7d74a1282c2d3b9bb42eaf7bf51ba75″>

<div class=”view-content”>

<h3>Lead Filer</h3>
<div class=”views-row”>
<div class=”views-field views-field-nothing”><span class=”field-content”> John Chevedden</span></div><div class=”views-field views-field-title views-field-field-shareholder”><span class=”field-content”>Chevedden Corporate Governance</span></div>
</div>

</div>

</div>
</div>

</div>
</div>

</div>
</div>
</aside&gt 

 

Resolution Details

Company:

Thermo Fisher Scientific Inc.

Year:

2024

Issue Area:

Human Rights & Worker Rights

Focus Area:

China, Human Rights

Status:

Withdrawn for Agreement

Resolution Text

Shareholders are concerned that Thermo Fisher Scientific (“the Company”) has signed sales agreements with police forces in occupied Tibet to supply Human Identification (HID) products. Two reports have been published outlining how authorities across Tibet have collected DNA from as many as 1.2 million Tibetans – including children as young as 5 years old without consent from their parents. [1]

Tibet is a repressive policing environment, where ‘criminal activity’ includes criticizing the government, owning a picture of the Dalai Lama or teaching the Tibetan language to children. Engaging in these activities routinely results in detention and torture of Tibetans by the police.

The police in Tibet are accountable only to the Chinese Communist Party, with no free media, civil society or international observers to place checks on their conduct. As such, it appears impossible that Thermo Fisher can guarantee how the police will use its equipment once it reaches Tibet. 

Since October 2022 representatives of impacted communities have written to the Company five times to raise concerns of the use of the Company’s HID products by law enforcement in Tibet. Shareholders also raised the issue at the 2023 AGM. The company has responded, but not engaged with the key issues that police in occupied Tibet cannot be trusted to only use this DNA equipment for standard criminal investigations, and that they are engaged in an ethnically targeted program of DNA collection. Despite repeated requests, the Company has to date refused to meet with stakeholders.

There is evidence of state-run DNA harvesting across China [2], and the Company recognized the possibility of its products being used in human rights violations, which prompted it, “consistent with its values, ethics code, and policies,” to cease “any new sales of HID products to Xinjiang Public Security Bureaus (PSBs) in March of 2019.”

RESOLVED, Shareholders request the Board of Directors to produce annually a Human Rights Impact Assessment regarding the sale (directly and via third parties) of the Company’s HID Products to law enforcement agencies. Reports to provide clear explanations of evidence examined and decisions made regarding permitting sales to law enforcement in regions where the use of such products could reasonably be expected to violate human rights. Such a report may exclude proprietary or legally privileged information. 

SUPPORTING STATEMENT: Proponents suggest that in such an Impact Assessment the company includes, or explains why it cannot disclose: 

A clear assessment of the nature of the policing environment
Disproportionality in policing experienced by different demographics of the population
Proportion of children subjected to DNA testing 
Examination of any reports of police-led mass DNA collection, in particular those targeted based on race, ethnicity or other characteristics for regions where the company sells, or proposes to sell, HID products to law enforcement agencies.

 

[1] Emile Dirks, ‘Mass DNA Collection in the Tibet Autonomous Region from 2016–2022, Citizen Lab, 13 September 2022;

[2] China’s sitting on a goldmine of genetic data – and it doesn’t want to share CNN, 12 August 2023

 

 

Resolution Details

Company:

Thermo Fisher Scientific Inc.

Year:

2023

Issue Area:

Inclusiveness

Focus Area:

Equal Employment Opportunity (EEO)

Status:

Withdrawn for Agreement

Resolution Text

BE IT RESOLVED: Shareholders request that Thermo Fisher Scientific Inc. (“Thermo Fisher”) report to shareholders on the effectiveness of the Company’s diversity, equity, and inclusion efforts. The report should be done at reasonable expense, exclude proprietary information, and provide transparency on outcomes, using quantitative metrics for hiring, retention, and promotion of employees, including data by gender, race, and ethnicity.

SUPPORTING STATEMENT: Quantitative data is sought so investors can assess and compare the effectiveness of companies’ diversity, equity, and inclusion programs.

WHEREAS: Thermo Fisher has not shared sufficient quantitative hiring, retention, and promotion data to allow investors to determine the effectiveness of its human capital management programs. Best practice disclosure includes hiring, retention, and promotion rate data by gender, race, and ethnicity in line with Equal Employment Opportunity Commission (EEOC) defined categories.

Between September 2020 and September 2022, S&P 100 companies increased by 298 percent their release of hiring rate data by gender, race, and ethnicity; retention rate data by 481 percent; and promotion rate data by 300 percent.1

Companies that release, or have committed to release, more inclusion data than Thermo Fisher include Gilead Sciences, Illumina, Quest Diagnostics, and Zoetis. Thermo Fisher is increasingly a laggard in its decision to continue to withhold these data sets.

Numerous studies have pointed to the benefits of a diverse workforce:

There is a positive association between diversity in management and cash flow, net profit, revenue, and return on equity.2
Companies in the top quartile for gender diversity are 21 percent more likely to outperform on profitability.3
The 20 most diverse companies had an average annual five-year stock return that was 5.8 percentage points higher than the 20 least diverse companies.4

Hiring, promotion and retention rate data show how well a company manages its workforce diversity. Without this data, investors are unable to assess the effectiveness of a company’s human capital management program.

Companies should look to hire the best talent. However, Black and Latino applicants face hiring challenges. Results of a meta-analysis of 24 field experiments found that, with identical resumes, White applicants received an average of 36 percent more callbacks than Black applicants and 24 percent more callbacks than Latino applicants.5

Promotion rates show how well diverse talent is nurtured at a company. Unfortunately, women and employees of color experience “a broken rung” in their careers; for every 100 men who are promoted, only 86 women are. Women of color are particularly impacted, comprising 17 percent of the entry-level workforce and only four percent of executives.6

Retention rates show whether employees choose to remain at a company. Morgan Stanley has found that employee retention above industry average can indicate a competitive advantage and higher levels of future profitability.7 Companies with high employee satisfaction have also been linked to annualized outperformance of over two percent.8

Investors have reason to be concerned as Thermo Fisher has faced allegations of race, gender, veteran, and disability discrimination.

1 https://www.asyousow.org/our-work/social-justice/workplace-equity
2 https://www.asyousow.org/report-pages/workplace-diversity-and-financial-performance
3 Ibid
4 https://www.wsj.com/articles/the-business-case-for-more-diversity-11572091200
5 https://hbr.org/2017/10/hiring-discrimination-against-black-americans-hasnt-declined-in-25-years
6 https://wiw-report.s3.amazonaws.com/Women_in_the_Workplace_2021.pdf
7 https://www.morganstanley.com/im/publication/insights/articles/article_culturequantframework_us.pdf
8 https://www.institutionalinvestor.com/article/b1tx0zzdhhnf5x/Want-to-Pick-the-Best-Stocks-Pick-the-Happiest- Companies?utm_medium=email&utm_campaign=The%20Essential%20II%20100721&utm_content=The%20Essential %20II%20100721%20CID_eb103a9e15359075f72a85f7ff534c79&utm_source=CampaignMonitorEmail&utm_term=W ant%20to%20Pick%20the%20Best%20Stocks%20Pick%20the%20Happiest%20Companies

  

​ 

Resolution Details

Company:

Thermo Fisher Scientific Inc.

Year:

2023

Issue Area:

Human Rights & Worker Rights

Focus Area:

Workplace Equity

Status:

Withdrawn for Agreement

Resolution Text

Whereas: Pay inequities persist across race and gender and pose substantial risks to companies and society. Black workers’ hourly median earnings represent 64 percent of white wages. The median income for women working full time is 83 percent that of men. Intersecting race, Black women earn 63 percent, Native women 60 percent, and Latina women 55 percent. At the current rate, women will not reach pay equity until 2059, Black women in 2130, and Latina women in 2224.1

Citigroup estimates closing minority and gender wage gaps 20 years ago could have generated 12 trillion dollars in additional national income. PwC estimates closing the gender pay gap could boost Organization for Economic Cooperation and Development (OECD) countries’ economies by 2 trillion dollars annually.2

Actively managing pay equity is associated with improved representation. Diversity in leadership is linked to superior stock performance and return on equity.3 Minorities represent 39 percent of Thermo Fisher’s workforce and 23 percent of executive management. Women represent 41.5 percent of the workforce and 35 percent of executive management.4

Best practice pay equity reporting consists of two parts:

unadjusted median pay gaps, assessing equal opportunity to high paying roles,

statistically adjusted gaps, assessing whether minorities and non-minorities, men and women, are paid the same for similar roles.

Thermo Fisher does not report quantitative unadjusted or adjusted pay gaps. Over 20 percent of the 100 largest U.S. employers currently report adjusted gaps, and an increasing number of companies disclose unadjusted gaps to address the structural bias women and minorities face regarding job opportunity and pay.5

Racial and gender unadjusted median pay gaps are accepted as the valid way of measuring pay inequity by the United States Census Bureau, Department of Labor, OECD, and International Labor Organization. The United Kingdom and Ireland mandate disclosure of median pay gaps, and the United Kingdom is considering racial pay reporting.6

Resolved: Shareholders request Thermo Fisher Scientific Inc. report on both quantitative median and adjusted pay gaps across race and gender, including associated policy, reputational, competitive, and operational risks, and risks related to recruiting and retaining diverse talent. The report should be prepared at reasonable cost, omitting proprietary information, litigation strategy and legal compliance information.

Racial/gender pay gaps are defined as the difference between non-minority and minority/male and female median earnings expressed as a percentage of non-minority/male earnings (Wikipedia/OECD, respectively).

Supporting Statement: An annual report adequate for investors to assess performance could, with board discretion, integrate base, bonus and equity compensation to calculate:

percentage median and adjusted gender pay gap, globally and/or by country, where appropriate

percentage median and adjusted racial/minority/ethnicity pay gap, US and/or by country, where appropriate

1https://static1.squarespace.com/static/5bc65db67d0c9102cca54b74/t/622f4567fae4ea772ae60492/1647265128087/Racial+Gender+Pay+Scorecard+2022+- +Arjuna+Capital.pdf
2 Ibid.
3 Ibid.
42021_CSR Report Thermo Fisher Scientific.pdf
5 https://diversiq.com/which-sp-500-companies-disclose-gender-pay-equity-data/ 6https://static1.squarespace.com/static/5bc65db67d0c9102cca54b74/t/622f4567fae4ea772ae60492/1647265128087/Racial+Gender+Pay+Scorecard+2022+- +Arjuna+Capital.pdf

  

​